Drugs / Iparomlimab
Iparomlimab
also known as
QL-1706 · QL1604 · Iparomlimab/Tuvorlimab · Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen
Trials 72 · started per year
today
2
1
44
25
2021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05801094 | Jul 2020 → Apr 2023 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06602063 | Jul 2025 → Jun 2030 expected | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Shanghai Gynecologic Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 259 trials | ||||||
| Phase 2 | NCT07663513 | Jul 2026 → Apr 2029 expected | ovarian cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07617818 | Jun 2026 → Jun 2028 expected | cervical cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07446387 | May 2026 → Dec 2028 expected | colorectal cancer | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07515469 | May 2026 → May 2028 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07502014 | May 2026 → Dec 2028 expected | colorectal cancer | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07041788 | Apr 2026 → Jul 2028 expected | cancer | Second Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07549906 | Apr → Jul 2026 overdue | malignant colon neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07490002 | Apr 2026 → Nov 2028 expected | esophageal squamous cell carcinoma | Changhai Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07379398 | Apr 2026 → Jun 2029 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07514793 | Apr 2026 → Apr 2029 expected | mesothelioma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07400315 | Mar 2026 → Dec 2028 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07277972 | Feb 2026 → Nov 2029 expected | clear cell renal carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07348861 | Feb 2026 → Jan 2028 expected | cervical cancer | Zheng Min | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07407452 | Feb 2026 → Dec 2027 expected | ovarian cancer | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07333287 | Feb 2026 → Feb 2027 expected | digestive system carcinoma | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07347444 | Feb 2026 → Dec 2028 expected | acral lentiginous melanoma, mucosal melanoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07349225 | Jan 2026 → Dec 2027 expected | small cell lung carcinoma | The Second Affiliated Hospital of Dalian Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07103395 | Jan 2026 → Dec 2029 expected | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07291401 | Jan 2026 → Jan 2027 expected | rectal cancer | Zhongnan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07315854 | Nov 2025 → Dec 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07330596 | Oct 2025 → Jan 2028 expected | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07101744 | Oct 2025 → Jul 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07152769 | Oct 2025 → Feb 2028 expected | intrahepatic cholangiocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07447570 | Oct 2025 → Dec 2027 expected | head and neck cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07103408 | Oct 2025 → Sep 2029 expected | small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07139041 | Oct 2025 → Apr 2027 expected | non-small cell lung carcinoma | Chang Chen | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07290010 | Sep 2025 → Dec 2026 expected | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07156682 | Sep 2025 → Jun 2027 expected | colon carcinoma | Qilu Hospital of Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07148427 | Sep 2025 → Dec 2027 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07038629 | Sep 2025 → Sep 2026 expected | esophageal cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07082179 | Sep 2025 → Dec 2027 expected | non-small cell lung carcinoma | Jiangsu Cancer Institute & Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07127822 | Sep 2025 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Peking University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07151209 | Sep 2025 → Dec 2028 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07116577 | Aug 2025 → Aug 2027 expected | colorectal cancer | Jinan Central Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07150377 | Aug 2025 → Aug 2026 overdue | hepatocellular carcinoma | The Second Affiliated Hospital of Shandong First Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07055399 | Aug 2025 → Sep 2026 expected | cervical cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06954116 | Aug 2025 → Dec 2028 expected | hepatocellular carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07129161 | Aug 2025 → Oct 2026 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07085234 | Jul 2025 → Dec 2027 expected | nasopharyngeal carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07090317 | Jul 2025 → Aug 2027 expected | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07165847 | Jul 2025 → Sep 2028 expected | gastric cancer | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07035808 | Jul 2025 → Dec 2028 expected | cervical cancer | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07053332 | Jul 2025 → Dec 2027 expected | gastroesophageal adenocarcinoma | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06936748 | Jun 2025 → Jun 2028 expected | cancer | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07014150 | Jun 2025 → May 2027 expected | hepatocellular carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07025174 | Jun 2025 → Dec 2026 expected | cholangiocarcinoma, gallbladder cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06986057 | May 2025 → Jul 2026 overdue | cervical cancer | Shandong Tumor Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07267078 | May 2025 → Jan 2028 expected | biliary tract cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06949111 | May 2025 → Feb 2027 expected | colon carcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07310069 | May 2025 → May 2027 expected | gallbladder cancer | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06958484 | May 2025 → Oct 2026 expected | hepatocellular carcinoma | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07026422 | Apr 2025 → Nov 2026 expected | rectal cancer | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06930118 | Apr 2025 → Apr 2027 expected | colorectal cancer | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06932068 | Mar 2025 → Oct 2026 expected | Her2-receptor negative breast cancer, gastroesophageal adenocarcinoma | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 2 | NCT06852456 | Mar 2025 → Dec 2030 expected | esophageal squamous cell carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06942416 | Feb 2025 → Jul 2026 overdue | cervical cancer | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06864013 | Jan 2025 → Dec 2029 expected | rectal cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT04326829 | Jul 2020 → Dec 2022 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07613567 | Sep 2026 → Aug 2032 expected | cervical carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07686640 | Jul 2026 → Jul 2029 expected | rectal cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07619235 | Jul 2026 → Jul 2028 expected | biliary tract cancer | Xianglin Yuan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07502027 | Jun 2026 → Mar 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07004335 | Jul 2025 → Dec 2028 expected | autoimmune pulmonary disease due to PD-1 deficiency, melanoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07538193 | May 2026 → May 2029 expected | metastatic malignant neoplasm in the lymph nodes, non-small cell lung carcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07546383 | Apr 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | The Second Affiliated Hospital of Hainan Medical University | Recruiting | No outcome recorded |
| — | NCT07187674 | Dec 2025 → Jun 2028 expected | triple-negative breast carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07268131 | Dec 2025 → Oct 2026 expected | hepatocellular carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT07139587 | Sep 2025 → Aug 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Qingxia Li | Not yet recruiting | No outcome recorded |
| — | NCT07115550 | Aug 2025 → Aug 2027 expected | hepatocellular carcinoma | Huai'an First People's Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07291947 Background | Nov 2025 → Sep 2026 expected | cholangiocarcinoma | Wang Xin | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 73 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab | “Efficacy and Safety of Iparomlimab and Tuvonralimab(QL1706) Combined With Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy for High-risk...” NCT07035808 ↗71“PD-1/CTLA-4 combination antibody: Iparomlimab and Tuvonralimab， 5mg/kg on day 1, day 22, and day 43, administered via intravenous infusion, for a total of three cycles before...” NCT07053332 ↗ “Neoadjuvant TACE Plus Iparomlimab and Tuvonralimab （QL1706）and Adjuvant QL1706 in Resectable BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria: the...” NCT07268131 ↗ “A Single-Arm, Exploratory Study of Iparomlimab and Tuvonralimab (QL1706) Plus XELOX as Neoadjuvant Therapy in Patients With Microsatellite Stable (pMMR/MSS) Resectable Stage...” NCT07156682 ↗ “CAPEOX+Iparomlimab and Tuvonralimab (capecitabine 1000mg/m2 bid po d1-d14, q3w; oxaliplatin 130mg/m2 iv d1, q3w; Iparomlimab and Tuvonralimab 5mg/kg iv d1, q3w) for 4 cycles.” NCT06864013 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “A Randomized, Multicenter, Phase III Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer” NCT07613567 ↗ “Iparomlimab and Tuvonralimab: 7.5 mg/kg, IV, Q3W Lenvatinib: 12 mg (for body weight ≥60 kg) or 8 mg (for body weight ≤60 kg), po, qd” NCT07150377 ↗ “patients received iparomlimab (a novel humanized anti-PD-1 mAb, 200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W)” PMID 39529169 ↗ Nov 2024 “Iparomlimab and tuvonralimab injection will be administered at 5 mg/kg by intravenous infusion every 21 days for 6 cycles.” NCT07686640 ↗ “Iparomlimab injection (drug number QL-1706) is a novel combination antibody independently developed by Qilu Company.” NCT07330596 ↗ “Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer” NCT07379398 ↗ “Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103408 ↗ “Iparomlimab (QL1604) is a humanized immunoglobulin G4 mAb against programmed cell death protein 1 (PD-1).” PMID 39276185 ↗ Sep 2024 “It consists of the anti-PD-1 antibody iparomlimab and the anti-CTLA-4 antibody tuvonralimab.” NCT07617818 ↗ “After 1-2 weeks Iparomlimab and Tuvonralimab (50 mg/2 mL) combined with Apatinib 250 mg qd” NCT07333287 ↗ “PD-1/CTLA-4 Dual Functional Antibody (iparomlimab and tuvonralimab injection):” NCT07025174 ↗ “Iparomlimab and Tuvonralimab (QL1706)” NCT07291401 ↗ |
| Known as | Iparomlimab/Tuvorlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085234 ↗ |
| Known as | Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085234 ↗ |
| Known as | QL-1706 | “After enrollment, the patients will receive induction therapy with Iparomlimab/Tuvorlimab(QL-1706) in combination with a modified TPF regimen, followed by concurrent...” NCT07085234 ↗1“Iparomlimab injection (drug number QL-1706) is a novel combination antibody independently developed by Qilu Company.” NCT07330596 ↗ |
| Known as | QL1604 | “Iparomlimab (QL1604) is a humanized immunoglobulin G4 mAb against programmed cell death protein 1 (PD-1).” PMID 39276185 ↗ Sep 20241“Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or” PMID 39529169 ↗ Nov 2024 |
| Action | Inhibit | “mAb against programmed cell death protein 1 (PD-1)” PMID 39276185 ↗ Sep 2024 |
| Modality | Monoclonal antibody | “a novel humanized anti-PD-1 mAb” PMID 39529169 ↗ Nov 2024 |
| Route | Intravenous | “200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W” PMID 39529169 ↗ Nov 2024 |